Celcuity Inc.
CELC
Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedaā¦ read more
Healthcare
Biotechnology
8 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$90.08
Price-3.16%
-$2.94
1Y
Price
Market Cap
$4.393b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$226.482m
-27.9%
1y CAGR-53.9%
3y CAGR-54.9%
5y CAGREPS
-$4.29
-13.5%
1y CAGR-17.4%
3y CAGR-13.2%
5y CAGRBook Value
-$12.781m
$828.220m
Assets$841.001m
Liabilities$754.385m
DebtDebt to Assets
91.1%
-4.1x
Debt to EBITDAFree Cash Flow
-$192.156m
-25.2%
1y CAGR-54.6%
3y CAGR-53.2%
5y CAGRNo items found.
Press Releases
Statements and updates from the company